Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 32 Hodgkin Disease 29 Lymphoma 10 Sarcoma 7 Uveal Melanoma 5 Neoplasm Metastasis 4 Neoplasms 3 Leiomyosarcoma 2 HIV Infections 2 Solitary Fibrous Tumors 1 Solid Tumor 1 Skin Neoplasms 1 Sarcoma, Synovial 1 Recurrence 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neurofibrosarcoma 1 Neuroendocrine Tumors 1 Neuroblastoma 1 Lymphoma, T-Cell, Peripheral 1 Immunotherapy 1 Hyperthermia 1 Hematologic Diseases 1 Carcinoma 1 Advanced Melanoma 1 Acquired Immunodeficiency Syndrome 1 AIDS-Related Complex 1

Interventions

tislelizumab 2 Oxaliplatin 2 tremelimumab 1 olaparib 1 durvalumab 1 apatinib 1 Tegafur 1 Dacarbazine 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Immunotherapy × Dacarbazine × Clear all

NCT04225390 2026-02-10

PROMIT

University of Erlangen-Nürnberg Medical School

Phase 2 Completed

Immunotherapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡